Is anyone in the LY2875358 trial?

Fox was our MDX poster boy until recently switching to IL-2, but I'm pretty sure you know his story, he had very few side effects at all.  Alice's husband John (one putt) is doing well in the MDX/Votrient trial I believe.

MDCinSC said:

Lets hear it for memory foam

Lets hear it for memory foam pillows! 

 

Sounds like an investment I need to make!

I was on it for about 18 months and had virtualy no side effects. Fatigue some times. But it was soooo easy. In the end it just couldn't clear up some bone mets although it did clear them initially. I say go for it. Other drugs will be available later.

I do not think it he LY2875358 and the MDX/BMS936558 are the same trial drugs. The LY (from what I read) is blocking a different receptor. I'm not a doctor and I didn't stay at a Holiday Inn, so I could be wrong.

Phoenix Rising said:

Lucky to get LY2875358?

My oncologist told me God must be on my side because there were only 5 slots for this trial in this region, and I got a slot when someone else dropped off the list.  He did not know what caused the other person to leave the trial but he believes they left before they even started the trial. He is very confident this will work well for me.

 

 

 

 

When I was asked to either asked to enter the trial, my doctor said something that I think is very wise.

if the trial doesn't provide what we hope for, then we have another decision to make. Do not think of it as failing, think of it as just another decision in the figsexism my Ming it is a decision to fight!

Phoenix Rising said:

I thought something way different

I thought that each time the study drug passes a phase, the name changes.... like BMS means it's Bristol Meyers Squibb, and LY is for Eli Lily and Company, or that the name changes based on the sponsor, collaborator, or party responsible for the trial.  I don't really know a lot, but I did save money on my car insurance.

Phoenix, you do seem to have got yourself awfully confused over the trial you're talking about, over the trials process, and over drug names.  I hope I can clarify matters for you.

The trial that was being suggested to you has nothing whatsoever to do with the MDX-1106 trial Fox was on. Nor is the drug in any way connected - different manufacturers, different chemistry, different drug, different generation of drug also, and different trial stage.  This trial is for what I believe is a third generation humanised monoclonal antibody agent - i.e. some way on from Fox's famous trial drug which is an immunomodulator of the same kind, and it represents a me-too attempt by another rival to cash in on the spectacular early promise of MDX-1106. 

[The various big pharma concerns are always busy trying to avoid any of their number getting the drop on the rest with a runaway success going unchallenged.  To a great extent it's a 'zero-sum game' - one gains at the extent of the others in competing to meet each particular need.  It's a dog-eat-dog world with such mammoth R & D costs that each company is at times at risk of going over the patent cliff as the deadline for their big money-spinners approaches and the legal protection expires which prevents anyone else from producing it at a knock-down price.]

You can get a lot of useful information about the drug which is the subject of the trial proposed for you at

http://www.prnewswire.com/news-releases/lilly-targets-faulty-c-met-receptor-in-cancer-research-studies-presented-today-at-aacr-meeting-145788385.html

When a drug is at an experimental stage prior to trial and (it's hoped approval later on) it's usually given a pretty anodyne label - typically alphabetic - abbreviation of the company's name - plus a number (normally just the next one sequentially in their development lists.  So, for 'your' trial Eli Lilly have called it LY + a reference no.

The history of 'Fox's' drug is that it as developed in East and West.  In the West it was made by Medarex - hence the earlier moniker MDX.     Medarex was bought out by Bristol Myers Squibb who thereupon re-named it for their co. as BMS.  Meanwhile it was developed and sold in 3 Asian countries by Ono Pharmaceuticals who, of curse, labelled it ONO.  Meanwhile, the assignment of an official generic name was in progress and this emerged last year as "nivolumab".  It will continue to be so called as a chemical name but doubtless after it gains FDA approval (it seems highly improbable that it won't!!) the manufacturers will invent brand names for it.  I say names becaus if the present licence arrangement continues it will be going out from separate makers in east and west.

I hope this clears it up for you and I hope you stay well and continue to save money on car insurance. 

Texas_wedge said:

Drug names

Phoenix, you do seem to have got yourself awfully confused over the trial you're talking about, over the trials process, and over drug names.  I hope I can clarify matters for you.

The trial that was being suggested to you has nothing whatsoever to do with the MDX-1106 trial Fox was on. Nor is the drug in any way connected - different manufacturers, different chemistry, different drug, different generation of drug also, and different trial stage.  This trial is for what I believe is a third generation humanised monoclonal antibody agent - i.e. some way on from Fox's famous trial drug which is an immunomodulator of the same kind, and it represents a me-too attempt by another rival to cash in on the spectacular early promise of MDX-1106. 

[The various big pharma concerns are always busy trying to avoid any of their number getting the drop on the rest with a runaway success going unchallenged.  To a great extent it's a 'zero-sum game' - one gains at the extent of the others in competing to meet each particular need.  It's a dog-eat-dog world with such mammoth R & D costs that each company is at times at risk of going over the patent cliff as the deadline for their big money-spinners approaches and the legal protection expires which prevents anyone else from producing it at a knock-down price.]

You can get a lot of useful information about the drug which is the subject of the trial proposed for you at

http://www.prnewswire.com/news-releases/lilly-targets-faulty-c-met-receptor-in-cancer-research-studies-presented-today-at-aacr-meeting-145788385.html

When a drug is at an experimental stage prior to trial and (it's hoped approval later on) it's usually given a pretty anodyne label - typically alphabetic - abbreviation of the company's name - plus a number (normally just the next one sequentially in their development lists.  So, for 'your' trial Eli Lilly have called it LY + a reference no.

The history of 'Fox's' drug is that it as developed in East and West.  In the West it was made by Medarex - hence the earlier moniker MDX.     Medarex was bought out by Bristol Myers Squibb who thereupon re-named it for their co. as BMS.  Meanwhile it was developed and sold in 3 Asian countries by Ono Pharmaceuticals who, of curse, labelled it ONO.  Meanwhile, the assignment of an official generic name was in progress and this emerged last year as "nivolumab".  It will continue to be so called as a chemical name but doubtless after it gains FDA approval (it seems highly improbable that it won't!!) the manufacturers will invent brand names for it.  I say names becaus if the present licence arrangement continues it will be going out from separate makers in east and west.

I hope this clears it up for you and I hope you stay well and continue to save money on car insurance. 

When will I learn there is no need to ask Google when there's Wedgie to ask? Thank you Tex for such a thorough explanation.